Literature DB >> 15168356

Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies.

H De Raeve1, E Van Marck, B Van Camp, K Vanderkerken.   

Abstract

Increased microvessel density (MVD) has been observed in the bone marrow (BM) of patients with multiple myeloma (MM), acute lymphoblastic leukaemia, acute myeloid leukaemia, and myelodysplastic and myeloproliferative syndrome. The MVD is the net result of cumulative phases of angiogenesis and angio-regression and is as such not an indicator of the ongoing angiogenesis at the time of biopsy. There is, therefore, a need for additional methods that allow the estimation of ongoing angiogenesis. Double immunostainings for CD34 and Ki-67 can be used on paraffin-embedded tissue to determine the endothelial proliferation fraction. The BM endothelial cells, as a component of the BM stroma, have a close interaction with the malignant cells. In MM, for example, they are involved in the specific homing and are a source of paracrine growth factors. Targeting the BM microvessels will not only influence the nutrient and oxygen supply, but will in addition reduce the growth stimuli provided by the EC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15168356     DOI: 10.14670/HH-19.935

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  6 in total

1.  Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB.

Authors:  Lara F Costa; Mercedes Balcells; Elazer R Edelman; Lee M Nadler; Angelo A Cardoso
Journal:  Blood       Date:  2005-09-01       Impact factor: 22.113

2.  Retrovirus-transformed erythroleukemia cells induce central nervous system failure in a new syngeneic mouse model of meningeal leukemia.

Authors:  Gordon R Macpherson; Charlotte A Hanson; Delores M Thompson; Christine M Perella; Joan L Cmarik; Sandra K Ruscetti
Journal:  Leuk Res       Date:  2011-09-15       Impact factor: 3.156

Review 3.  Biological aspects of angiogenesis in multiple myeloma.

Authors:  Eléonore Otjacques; Marilène Binsfeld; Agnes Noel; Yves Beguin; Didier Cataldo; Jo Caers
Journal:  Int J Hematol       Date:  2011-11-17       Impact factor: 2.490

4.  CD34 and p53 immunohistochemical stains differentiate hypocellular myelodysplastic syndrome (hMDS) from aplastic anemia and a CD34 immunohistochemical stain provides useful survival information for hMDS.

Authors:  Choong-Hwan Cha; Chan-Jeoung Park; Hyun-Sook Chi; Eul Ju Seo; Seongsoo Jang; Young-Uk Cho; Kyoo-Hyung Lee; Je-Hwan Lee; Jung-Hee Lee; Ho Joon Im; Jong-Jin Seo
Journal:  Ann Lab Med       Date:  2014-10-28       Impact factor: 3.464

5.  Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients.

Authors:  Valentina Marchica; Denise Toscani; Anna Corcione; Marina Bolzoni; Paola Storti; Rosanna Vescovini; Elisa Ferretti; Benedetta Dalla Palma; Emanuela Vicario; Fabrizio Accardi; Cristina Mancini; Eugenia Martella; Domenico Ribatti; Angelo Vacca; Vito Pistoia; Nicola Giuliani
Journal:  Cancers (Basel)       Date:  2019-03-06       Impact factor: 6.639

6.  Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia.

Authors:  C-Y Lee; H-F Tien; C-Y Hu; W-C Chou; L-I Lin
Journal:  Br J Cancer       Date:  2007-09-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.